IL281965B1 - Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases - Google Patents

Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases

Info

Publication number
IL281965B1
IL281965B1 IL281965A IL28196521A IL281965B1 IL 281965 B1 IL281965 B1 IL 281965B1 IL 281965 A IL281965 A IL 281965A IL 28196521 A IL28196521 A IL 28196521A IL 281965 B1 IL281965 B1 IL 281965B1
Authority
IL
Israel
Prior art keywords
treatment
type
sulfonamide compounds
collagen diseases
biphenyl sulfonamide
Prior art date
Application number
IL281965A
Other languages
English (en)
Hebrew (he)
Other versions
IL281965A (en
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of IL281965A publication Critical patent/IL281965A/en
Publication of IL281965B1 publication Critical patent/IL281965B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL281965A 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases IL281965B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (2)

Publication Number Publication Date
IL281965A IL281965A (en) 2021-05-31
IL281965B1 true IL281965B1 (en) 2026-04-01

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281965A IL281965B1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases

Country Status (13)

Country Link
US (1) US11207299B2 (https=)
EP (1) EP3860594B1 (https=)
JP (2) JP7524167B2 (https=)
KR (1) KR102902972B1 (https=)
CN (1) CN113286587A (https=)
AU (1) AU2019354784B2 (https=)
BR (1) BR112021006132A2 (https=)
CA (1) CA3114434A1 (https=)
ES (1) ES3057657T3 (https=)
IL (1) IL281965B1 (https=)
MA (1) MA53817A (https=)
MX (1) MX2021003606A (https=)
WO (1) WO2020072814A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
US20220048900A1 (en) 2018-12-21 2022-02-17 Travere Therapuetics, Inc. Amorphous sparsentan compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRANK T.L. VAN DER LOOP ET AL,, AUTOSOMAL DOMINANT ALPORT SYNDROME CAUSED BY A COL4A3 SPLICE SITE MUTATION, 1 November 2000 (2000-11-01) *
MEEHAN, DANIEL T ET AL.,, ENDOTHELIN-1 MEDIATED INDUCTION OF EXTRACELLULAR MATRIX GENES IN STRIAL MARGINAL CELLS UNDERLIES STRIAL PATHOLOGY IN ALPORT MICE, 21 August 2016 (2016-08-21) *
SHARON G. ADLER ET AL,, GLOMERULAR TYPE IV COLLAGEN IN PATIENTS WITH DIABETIC NEPHROPATHY WITH AND WITHOUT ADDITIONAL GLOMERULAR DISEASE, 1 May 2000 (2000-05-01) *

Also Published As

Publication number Publication date
JP7524167B2 (ja) 2024-07-29
MX2021003606A (es) 2021-08-16
BR112021006132A2 (pt) 2021-07-20
US20200147050A1 (en) 2020-05-14
JP2024133735A (ja) 2024-10-02
MA53817A (fr) 2021-08-11
CN113286587A (zh) 2021-08-20
EP3860594B1 (en) 2025-10-01
CA3114434A1 (en) 2020-04-09
AU2019354784A1 (en) 2021-04-15
IL281965A (en) 2021-05-31
WO2020072814A1 (en) 2020-04-09
JP2022514152A (ja) 2022-02-10
AU2019354784B2 (en) 2025-07-10
US11207299B2 (en) 2021-12-28
ES3057657T3 (en) 2026-03-03
KR20210081338A (ko) 2021-07-01
KR102902972B1 (ko) 2025-12-22
EP3860594A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
SG11202104705RA (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
PT3600309T (pt) Combinações terapêuticas para o tratamento de doenças hepáticas
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
IL279260A (en) KDM1A inhibitors for the treatment of diseases
EP3221321A4 (en) Fused bicyclic compounds for the treatment of disease
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3140291A4 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
IL281965A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
IL248668B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
ZA201807509B (en) Di-substituted pyrazole compounds for the treatment of diseases
PL3210973T3 (pl) Związki heteroarylowe do leczenia chorób oczu
SG11202103253YA (en) Therapeutic compounds
GB201805100D0 (en) Treatment of sarcopenic diseases
HUE069820T2 (hu) Nalfurafin alkalmazása demielinizációs betegségek kezelésére
GB201808150D0 (en) Therapeutic compounds
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
ME03056B (me) Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac
EP3261635A4 (en) Compounds for treating ocular diseases
HK40012876A (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
HK40061035A (en) Novel compounds for the treatment of respiratory diseases
HK40049516A (en) Kdm1a inhibitors for the treatment of disease
GB201805099D0 (en) Treatment of osteoporotic diseases
GB201811912D0 (en) Treatment of disease